KDM6B inhibition enhances chemotherapeutic response in small cell lung cancer via epigenetic regulation of apoptosis and ferroptosis
Finally, in vivo experiments using patient-derived xenograft (PDX) models demonstrated that Gskj1 effectively enhances the antitumor efficacy of chemotherapy in SCLC, providing compelling evidence for the clinical potential of targeting KDM6B to overcome chemoresistance.
Authors
- Yufan Yang (ORCID: https://orcid.org/0000-0002-9036-2640)
- Linlang Guo (ORCID: https://orcid.org/0000-0002-1859-7592)
- Shumei Liang (ORCID: https://orcid.org/0000-0001-9326-3907)
- Man Li (ORCID: https://orcid.org/0000-0002-7480-0401)
- Qian Chen (ORCID: https://orcid.org/0000-0002-3585-305X)
- Zhongliang Wang (ORCID: https://orcid.org/0000-0001-9388-149X)
- Ziyuan Liu (ORCID: https://orcid.org/0000-0003-2369-4255)
- Wenyang Wang
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou First People's Hospital (CN)
- Zhujiang Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s13578-025-01496-6
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05